Anti-breast cancer action of carbonic anhydrase IX inhibitor 4-[4-(4-Benzo[1,3]dioxol-5-ylmethyl-piperazin-1-yl)-benzylidene-hydrazinocarbonyl]-benzenesulfonamide (BSM-0004): in vitro and in vivo studies
Open Access
- 1 January 2021
- journal article
- research article
- Published by Taylor & Francis in Journal of Enzyme Inhibition and Medicinal Chemistry
- Vol. 36 (1) , 954-963
Abstract
Anti-breast cancer action of novel human carbonic anhydrase IX (hCA IX) inhibitor BSM-0004 has been investigated using in vitro and in vivo models of breast cancer. BSM-0004 was found to be a potent and selective hCA IX inhibitor with a Ki value of 96 nM. In vitro anticancer effect of BSM-0004 was analysed against MCF 7 and MDA-MA-231 cells, BSM-0004 exerted an effective cytotoxic effect under normoxic and hypoxic conditions, inducing apoptosis in MCF 7 cells. Additionally, this compound significantly regulates the expression of crucial biomarkers associated with apoptosis. The investigation was extended to confirm the efficacy of this hCA IX inhibitor against in vivo model of breast cancer. The results specified that the treatment of BSM-0004 displayed an effective in vivo anticancer effect, reducing tumour growth in a xenograft cancer model. Hence, our investigation delivers an effective anti-breast cancer agent that engenders the anticancer effect by inhibiting hCA IX.Keywords
Funding Information
- National Research Foundation of Korea (NRF) Republic of Korea ((MSIP)NRF-2020R1A2C1102100, NRF-2016R1A5A1011974)
- National Research Foundation of Korea (2019H1D3A2A02102142, 2019R1F1A1057386)
- Korean government
This publication has 62 references indexed in Scilit:
- Carbonic anhydrase IX from cancer-associated fibroblasts drives epithelial-mesenchymal transition in prostate carcinoma cellsCell Cycle, 2013
- Anticancer carbonic anhydrase inhibitors: a patent review (2008 – 2013)Expert Opinion on Therapeutic Patents, 2013
- Mechanisms of Action of Bcl-2 Family ProteinsCold Spring Harbor Perspectives in Biology, 2013
- Carbonic anhydrase inhibition as a cancer therapy: a review of patent literature, 2007 – 2009Expert Opinion on Therapeutic Patents, 2010
- Carbonic anhydrase IX: Biochemical and crystallographic characterization of a novel antitumor targetBiochimica et Biophysica Acta (BBA) - Proteins and Proteomics, 2010
- Carbonic anhydrase IX: A new druggable target for the design of antitumor agentsMedicinal Research Reviews, 2007
- Targeting tumor-associated carbonic anhydrase IX in cancer therapyTrends in Pharmacological Sciences, 2006
- Role of Carbonic Anhydrase IX in Human Tumor Cell Growth, Survival, and InvasionCancer Research, 2004
- Modulation of carbonic anhydrase activity and its applications in therapyExpert Opinion on Therapeutic Patents, 2004
- Carbonic anhydrase inhibitors and their therapeutic potentialExpert Opinion on Therapeutic Patents, 2000